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Combining 18F-FDG positron 
emission tomography with Up-to-
seven criteria for selecting suitable 
liver transplant patients with 
advanced hepatocellular carcinoma
Arno Kornberg1, Ulrike Witt1, Martina Schernhammer1, Jennifer Kornberg2, Gueralp O. 
Ceyhan1, Katharina Mueller3, Helmut Friess1 & Katharina Thrum4
The Up-to-seven (UTS) criteria (sum of tumor size and number not exceeding 7) for indicating liver 
transplantation (LT) in hepatocellular carcinoma (HCC) were originally based on explant pathology 
features and absence of microvascular invasion (MVI). 18F-fludeoxyglucose (18F-FDG) positron emission 
tomography (PET) was shown to indicate the risk of MVI and tumor recurrence. The aim of this study 
was to analyze the prognostic significance of the clinical UTS criteria when being combined with 
PET-status of the tumor. Data of 116 liver transplant patients were subject to retrospective analysis. 
Five-year recurrence-free survival (RFS) rates in patients meeting (n = 85) and exceeding (n = 21) the 
radiographic UTS criteria were 81% and 55.1%, respectively (p = 0.014). In the UTS In subset, RFS was 
significantly better in PET-negative (94.9%) than in PET-positive patients (48.3%; p < 0.001). In the UTS 
Out subset, 5-year RFS rates were 87.1% and 19% in patients with non- 18F-FDG-avid and 18F-FDG-avid 
tumors (p < 0.001), respectively. Positive PET-status was identified as the only independent clinical 
predictor of tumor recurrence in beyond UTS patients (Hazard ratio [HR] 19.25; p < 0.001). Combining 
radiographic UTS criteria with FDG-PET may safely expand the HCC selection criteria for LT.
Hepatocellular carcinoma (HCC) is currently the fifth most common cancer and the third most common reason 
of cancer-related death worldwide1,2. Surgical resection is the treatment of choice. However, due to underlying cir-
rhosis with related liver dysfunction, major hepatectomy is often not practicable3,4. From an oncological point of 
view, liver transplantation (LT) is the best treatment option, since it removes the tumor and the tumor-generating 
cirrhosis5,6. Early experiences with LT for HCC were limited by high recurrence rates and poor survival7,8. In a 
landmark study of 1996, Mazzaferro et al. were able to demonstrate that LT in early stage HCC leads to excel-
lent long-term outcome that was not different from patients with non-malignant diseases. Overall (OS) and 
recurrence-free survival (RFS) rates at 4 years post-LT were 85% and 92% for patients meeting the so-called Milan 
criteria (MC; one single HCC nodule of up to 5 cm, or a maximum of 3 tumor nodules, each not exceeding 3 cm 
and absence of macrovascular invasion), but only 50% and 59% for those exceeding them9,10. Consequently, the 
MC were implemented as standard for selecting suitable liver transplant recipients in the major allocation areas 
around the world.
In recent years, there is a growing concern that the MC may be too restrictive and inappropriate to satisfy 
continuously growing waiting list demands11,12. Several studies have shown that a subset of patients with HCC 
exceeding standard criteria may benefit from LT. Accordingly, numerous expanded criteria sets were proposed in 
the last two decades, such as the University of California (UCSF)13, Toronto14, Valencia15 and Hangzhou criteria16, 
to name just a few of them.
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In 2009, Mazaferro et al. introduced the so-called Up-to-seven (UTS) criteria by simply combining the larg-
est tumor nodule size and the number of HCC nodules, which should not exceed 7 in sum. In a large European 
multicenter trial including 1556 liver transplant recipients, they demonstrated that patients with HCC exceeding 
the MC but still meeting the UTS criteria have an excellent prognosis that was not different from patients meet-
ing standard criteria HCC17. However, the authors have used post-LT generated histopathologic and not pre-LT 
radiographic features for their investigation18. Apart from that, beneficial outcome of the expanded HCC subset 
was related to lack of microvascular tumor invasion (MVI)17.
Tumor invasion into microscopic vessels is recognized as a major indicator of aggressive tumor behaviour 
and poor outcome19,20. However, it may reliably be assessed only on explant pathology and not by conventional 
radiographic imaging21. Therefore, for a safe application of the UTS criteria, the implementation of appropriate 
clinical biomarkers of tumor aggressiveness seems to be mandatory20.
In recent years, several transplant groups were able to demonstrate that 18F-fludeoxyglucose (18F-FDG) pos-
itron emission tomography (PET) provides useful information on metabolic tumor viability and posttransplant 
outcome22–24. PET-positivity was shown to correlate with presence of unfavourable histopathologic features, like 
MVI and poor grading23,25,26.
The primary aim of this retrospective study was to analyze the prognostic value of the UTS criteria when being 
based on pretransplant imaging. Apart from that, we investigated whether the combination of the radiographic 
UTS criteria with 18F-FDG PET may be useful for predicting posttransplant tumor recurrence and, thus, for safely 
expanding the pool of suitable liver transplant patients.
Methods
Subjects. The study protocol was approved by the local Ethics Committee (Ethical committee of the Medical 
School, Technical University Munich, Nr. 217/15). Patients’ registration, waiting list management and transplant 
procedures were performed according to national law and re-gulations. Prior to LT, all patients gave informed 
consent that follow-up data may be used for study purpose and respective publication. This work was supported 
by the German research Foundation (DFG) and the Technische Universität München within the funding pro-
gramme Open Access Publishing.
From a prospectively updated data base (1996 to 2012; two-center study under same personal responsibilities 
and conditions), 116 patients that underwent LT for HCC were identified. Tumor diagnosis was established by 
clinical staging (radiographic imaging by computed tomography [CT] and/or magnetic resonance tomography 
[MRI] + alpha-fetoprotein level [AFP] measurement) without tumor biopsy. The minimum cut-off tumor nodule 
size for diagnostic purpose was 1 cm. The MC were primarily used for justifying patients’ listing.
Since December 2007, patients with HCC meeting the MC received exceptional priority status according to 
the model of end-stage liver disease (MELD) score. Based on HCC topography and remaining liver function, 
transarterial chemotherapy (TACE) as bridging to LT has been performed. Pretransplant tumor surveillance 
consisted of liver ultrasound and AFP level determination every 6 weeks, and CT/MRI scan minimum biannu-
ally. Additional radiographic imaging was performed when required, such as post-TACE, prior to MELD score 
upgrading and in the case of tumor-related symptoms.
Progression of tumor load beyond the MC resulted in loss of MELD exceptional priority status. Apart from 
that, a concise re-evaluation by computed tomography (CT) and/or magnetic resonance tomography (MRI) and 
AFP level determination every 3 months was initiated. According to an individual decision making process, 
these patients were primarily scheduled for center-based liver allocation, unless macrovascular tumor infiltration, 
lymph node infiltration or extrahepatic tumor spread (biological tumor progression) became evident.
18F-FDG PET was performed in all patients with liver malignancy in order to exclude extrahepatic tumor 
manifestation. The prospectively collected data were retrospectively used for the assessment of metabolic tumor 
properties.
As previously described, we distinguished between PET-positive (PET+ status; 18F-FDG-avid) and 
PET-negative (PET– status; non- 18F-FDG-avid) tumors. This classification was based on concise visual 
FDG-uptake assessment of each tumor nodule in very close morphological demarcation to the surrounding 
non-tumorous liver regions. Any significantly enhanced 18F-FDG uptake pattern compared to normal adjacent 
liver tissue (tumor to non-tumor maximum standard uptake value > 1) was indicating PET+ status of HCC22,23.
Based on final pretransplant radiographic staging, patients were classified as Milan In (HCC meeting the MC; 
Milan In) or Milan Out (HCC exceeding the MC; Milan Out), and UTS In (HCC meeting the UTS criteria; UTS 
In) and UTS Out (HCC exceeding the UTS criteria; UTS Out), respectively.
Transplant procedure and posttransplant follow-up. ABO-compatible deceased donor liver grafts 
were used for transplant procedure in all study patients. Venous reconstruction was performed by using the piggy 
back technique without veno-venous bypass. In order to avoid the theoretical risk of systemic tumor cell spread, 
we have not used intraoperative blood salvage autotransfusion. Posttransplant immunosuppression consisted 
of a calcineurin inhibitor based regimen either by cyclosporine A or tacrolimus augmented by azathioprine or 
mycophenolate mofetil. Prednisone was withdrawn latest 3 months post-LT with exception of pre-existing auto-
immune hepatitis. Tumor surveillance post-LT consisted of AFP-level determination and liver ultrasound at least 
every three months. Apart from that, CT scans of the chest and abdomen were performed every 6 months during 
the first posttransplant year and minimum thereafter or in case of suspected HCC relapse.
Statistical analysis. Categorical variables were compared using the χ2 test. Continuous variables were 
recorded by median and range, and compared using the Student’s t test.
The Kaplan-Meier method was performed to determine overall survival (OS) and recurrence-free survival 
(RFS) rates. Variables being significant for predicting HCC relapse in univariate analysis (p < 0.05) were entered 
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into a stepwise multivariate logistic Cox regression model in order to identify independent prognostic factors 
(p < 0.05). Only pretransplant available clinical features were included in the analysis. All statistical analyses were 
performed by using the software SPSS 23.0 (IBM Inc., Munich, Germany).
Results
Clinicopathologic characteristics. The baseline clinicopathologic characteristics are summarized in 
Table 1.
Preoperative PET imaging demonstrated 41 PET-positive (35.3%) and 75 PET-negative tumors (64.7%).
Based on clinical staging, 66 patients were classified as Milan In (56.9%) and 50 patients as Milan Out (43.1%), 
whereas tumors were meeting and exceeding the UTS criteria in 85 (73.3%) and 21 (26.7%) patients, respectively. 
UTS In and UTS Out patients did not significantly differ with regard to gender, age, liver diseases, Child classi-
fication, MELD score, AFP level, TACE and PET status. Explant histopathological studies revealed more tumors 
demonstrating with MVI in the UTS Out subset (Table 1).
Variable
All patients 
(n = 116)
UTS In 
(n = 85)
UTS Out 
(n = 31) p value
Gender
0.436 Male 68 (58.6%) 48 (56.5%) 20 (64.5%)
 Female 48 (41.4%) 37 (43.5%) 11 (35.5%)
Mean age recipients in years ± STD 58.7 ± 6.7 58.8 ± 7.1 58.6 ± 5.7 0.890
Liver disease
0.917
 Ethyltoxic 65 (56%) 46 (54.1%) 19 (61.3%)
 Hepatitis C 22 (19%) 18 (21.2%) 4 (12.9%)
 Hepatitis B 12 (10.3%) 9 (10.6%) 3 (9.7%)
 Autoimmun 4 (3.4%) 3 (3.5%) 1 (3.2%)
 Cholestatic 3 (2.6%) 2 (2.3%) 1 (3.2%)
 Other 10 (8.6%) 7 (8.2%) 3 (9.7%)
Child-Pugh
0.945 A 53 (45.7%) 39 (45.9%) 14 (45.2%)
 B/C 63 (54.3%) 46 (54.1%) 17 (54.8%)
Median (lab.)MELD score at LT 
(range) 16 (9–35) 16 (9–35) 18 (9–33) 0.504
Median AFP level in ng/ml at LT 
(range) 62 (1.5–46930) 50 (1.5–13300) 150 (3.2–46930) 0.111
TACE prior LT
0.456 Yes 76 (65.5%) 54 (63.5%) 22 (71%)
 No 40 (34.5%) 31 (36.5%) 9 (29%)
HCC nodules*
0.002 Solitary 58 (50%) 50 (58.8%) 8 (25.8%)
 Multifocal 58 (50%) 35 (41.2%) 23 (74.2%)
Median size of largest HCC nodule 
in cm (range)* 4 (1–20) 3 (1–6) 6 (3–20) <0.001
Median total tumor diameter in cm 
(range)* 5 (1–20) 5 (1–14) 10 (5.8–20) <0.001
Median tumor number (range)* 1.5 (1–8) 1 (1–5) 3 (1–8) <0.001
Milan criteria*
<0.001 In 66 (56.9%) 66 (77.6%) 0 (0%)
 Out 50 (43.1%) 19 (22.4%) 31 (100%)
PET-status
0.076 Negative 75 (64.7%) 59 (69.4%) 16 (51.6%)
 Positive 41 (35.3%) 26 (30.6%) 15 (48.4%)
Microvascular invasion
0.017 No 73 (62.9%) 59 (69.4%) 14 (45.2%)
 Yes 43 (37.1%) 26 (30.6%) 17 (54.8%)
Tumor differentiation
0.449 Well/moderate 95 (81.9%) 71 (83.5%) 24 (77.4%)
 Poor 21 (18.1%) 14 (16.5%) 7 (22.6%)
Table 1. Clinicopathologic characteristics of the study cohort (n = 116). *According to pretransplant 
radiographic imaging. 18F-FDG – 18F-fludeoxyglucose. AFP – alpha-fetoprotein. HCC – hepatocellular 
carcinoma. LT – liver transplantation. MELD – model for end-stage liver disease. PET – positron emission 
tomography. TACE – transarterial chemoembolization. UTS – Up-to-seven criteria
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Overall survival and tumor recurrence. Posttransplant follow-up was ranging between 5 and 184 months 
(median: 74). OS rates were 82.7% and 75.6% at 3 and 5 years post-LT. Posttransplant HCC relapse was confirmed 
in 29 patients (25%) after a median of 11 months (range: 4–55).
Corresponding RFS rates were 77.2% and 74.4% at 3 and 5 years, respectively.
In univariate analysis, AFP level, multiple tumor nodules, maximum tumor diameter, number of HCC 
nodules, UTS criteria and PET-status were significantly associated with risk of HCC recurrence. Only positive 
PET-status, AFP level > 400 ng/nl and manifestation of multiple HCC nodules were identified as significant and 
independent predictors of HCC recurrence on multivariate analysis (Table 2).
Outcome according to the Milan and UTS criteria. OS rates among Milan In and Milan Out patients 
were 89.4% and 81.7%, and 74% and 62.7% at 3 and 5 years post-LT (Fig. 1; p < 0.001). There were 9 HCC recur-
rences in the Milan In subset (13.6%), whereas 20 Milan Out patients (40%) developed tumor relapse (p = 0.001). 
RFS rates were 86.2% and 86.2% among Milan In patients, but only 65.4% and 58.4% in patients with Milan Out 
HCC (Fig. 2; p = 0.001).
We found significantly better OS in patients meeting (85.9%, 77.4%) than in those exceeding the UTS criteria 
(74.2%, 63.2%; p = 0.034; Fig. 3).
Sixteen UTS In (18.8%) and 13 beyond UTS patients (41.9%; p = 0.011) developed HCC recurrence.
Thus, RFS rates at 3- and 5-years post-LT were 81% and 81% in patients meeting, but only 66.7% and 55.1% in 
those exceeding the UTS criteria (p = 0.014; Fig. 4), respectively.
Variable p value HR (95% CI) p value
Male gender 0.663
Age recipients’ >60 y 0.519
Viral disease (n) 0.480
Child B/C 0.162
(Lab.)MELD >15 0.191
AFP prior to LT >400 ng/ml <0.001 10.13 (2.341–43.876) 0.002
No TACE pre-LT 0.367
Multiple HCC nodules* 0.005 4.65 (1.336–16.169) 0.016
Maximum HCC nodule size > 5 cm* 0.226
Maximum total tumor diameter > 10 cm* 0.038
Number HCC nodules > 3* 0.013
Exceeding UTS criteria 0.011
PET+ status <0.001 22.88 (6.303–83.008) <0.001
Table 2. Prognostic variables for HCC recurrence in the entire study group (n = 116). *According to 
pretransplant radiographic staging. AFP – alpha-fetoprotein. CI – confidence interval. HCC – hepatocellular 
carcinoma. LT – liver transplantation. MELD – model for end-stage liver disease. PET – positron emission 
tomography. TACE – transarterial chemoembolization. UTS – Up-to-seven criteria
Figure 1. Three and 5-year OS rates among Milan In and Milan Out patients were 89.4% and 81.7%, and 74% 
and 62.7%, respectively (log rank < 0.001).
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PET-positivity and presence of more than 3 tumor nodules were identified as the only significant and inde-
pendent clinical predictors of HCC recurrence among UTS In patients (Table 3). In this subset, RFS was signif-
icantly better in PET-negative (94.9%; 94.9%) than in PET-positive patients (48.3%; 48.3%; p < 0.001; Fig. 5).
Only PET-positivity remained as significant and independent predictor of HCC recurrence in beyond 
UTS patients (Table 4). In this subgroup, we recorded 3- and 5-year RFS rates of 93.8% and 87.1% in non- 
18F-FDG-avid, but only 35.7% and 19% in 18F-FDG-avid patients (p < 0.001; Fig. 6), respectively. RFS was com-
parable between UTS In and PET-negative beyond UTS patients (p = 0.534; Fig. 7).
Clinicopathologic differences between Milan In (n = 66), Milan Out/UTS In (n = 19), and beyond UTS 
patients (n = 31) are listed in Table 5.
Tumor recurrence rate was significantly lower, OS and RFS were both significantly better in Milan In patients 
as compared to the other two subsets. In contrast, there were no significant outcome differences between Milan 
Out/UTS In patients and patients with beyond UTS tumors (Table 5).
In the Milan Out/UTS In subgroup, 5-year RFS rates were 80% in PET-positive and 44.4% PET-negative 
patients (p = 0.078; Fig. 8). There was no significant difference in tumor-specific outcome between Milan In 
patients and patients with PET-negative Milan Out/UTS In tumors (p = 0.639; Fig. 9).
PET correlations with tumor characteristics and outcome. Table 6 describes the correlations of 
PET-status with clinicopathologic tumor variables and posttransplant outcome.
Figure 2. Posttransplant recurrence-free survival rates were 86.2% and 86.2% among Milan In patients, but 
only 65.4% and 58.4% in patients exceeding the MC (log rank = 0.001).
Figure 3. Overall survival at 3- and 5-years post-LT was significantly better in patients meeting the UTS criteria 
(85.9%, 77.4%) compared to those exceeding them (74.2%, 63.2%; log rank = 0.034).
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Positive PET-status correlated significantly with tumor nodule size and total tumor diameter, whereas it 
tended to be associated with elevated AFP levels. Apart from that, enhanced 18F-FDG uptake on PET was signif-
icantly correlated with presence of aggressive histopathologic features (Table 6).
Among PET-negative patients, OS and RFS rates were 97.3% and 88.7%, and 94.6% and 93.3% at 3- and 
5-years, which was significantly higher than in PET+ patients (63.4% and 46.3%; 43.8% and 38.1%; p < 0.001). 
Tumor recurrence rate was 6.7% in non- 18F-FDG-avid patients, but 58.5% in those with PET+ tumors (p < 0.001; 
Table 6).
Discussion
At first sight, our data seem to implicate that expansion to the clinical UTS criteria does not dramatically increase 
the risk of tumor recurrence. We found considerable 5year RFS rates in patients meeting the radiographic UTS 
criteria (81%), which was only slightly inferior to the Milan In cohort (86.2%). Apart from that, an additional of 
19 patients beyond the MC could, thereby, be declared as being suitable for LT (Table 5), which corresponds to 
an increase of 19.6%. Insofar, our study seems to validate the UTS criteria on basis of clinical staging. However, 
in the additionally recruited patients with tumors exceeding the MC but still meeting the UTS criteria (n = 19), 
the tumor recurrence rate was significantly higher (36.8% versus 13.6%; p = 0.023), and OS (62.2% versus 81.7%; 
p = 0.001) and RFS rates (63.2% versus 86.2%; p = 0.017) were both significantly lower compared to the Milan In 
subset (Table 5). Probably, just because of the small sample size, this has not yet become noticeable in the overall 
survival. Therefore, on closer examination, our data rather indicate that the undifferentiated application of the 
UTS criteria enhances the oncological risk.
Whether our results finally justify the implementation of the UTS criteria is a matter of critical discussion. 
Liberalizing the transplant criteria without expanding the pool of available donor organs results in growing wait-
ing lists and prolongation of pre-LT waiting times. This may in turn enhance the drop out risk following tumor 
Figure 4. Recurrence-free survival rates at 3- and 5-years post-LT were 81% and 81% in UTS In patients, but 
only 66.7% and 55.1% in UTS Out patients, respectively (log rank = 0.014).
Variable p value HR (95%CI) p value
Male gender 0.589
Age recipients’ > 60 y 0.205
Viral disease (n) 0.215
Child B/C 0.849
(Lab.)MELD > 15 0.750
AFP prior to LT > 400 ng/ml 0.001
No TACE pre-LT 0.502
Multiple HCC nodules* 0.013
Maximum HCC nodule size > 5 cm* 0.945
Maximum total tumor diameter > 10 cm* 0.491
Number HCC nodules > 3* 0.015 17.38 (1.443–208.103) 0.025
PET+ status <0.001 24.95 (5.01–124.226) <0.001
Table 3. Prognostic variables for HCC recurrence in UTS In patients (n = 85). *According to pretransplant 
radiographic staging. AFP – alpha-fetoprotein. CI – confidence interval. HCC – hepatocellular carcinoma. LT 
– liver transplantation. MELD – model for end-stage liver disease. PET – positron emission tomography. TACE 
– transarterial chemoembolization. UTS – Up-to-seven criteria.
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progression. Recently, Volk et al. identified a threshold survival of 61% at 5 years to be required for balancing ben-
efit and harm of LT in advanced HCC patients, at least in the US27. In our Milan Out/UTS In cohort, 5-year OS 
and RFS rates were 61% and 63.2% (Table 5), respectively, which exceeded this cut-off value. However, a tumor 
relapse risk about 40% in an additionally selected expanded criteria HCC subset may be unacceptable, particu-
larly in view of an escalating donor organ shortage28.
In recent years, several trials emphasized on the predictive power of the UTS criteria17,29–31. Nevertheless, they 
have not yet been implemented as standard for patients’ selection. It was a major limitation of these studies that 
pathomorphometric and not radiographic UTS features were used. Well-known discrepancies between pre- and 
posttransplant tumor staging may have limited clinical applicability32. Apart from that, absence of MVI contrib-
uted substantially to the prognostic value of the UTS criteria, which additionally hampered their implementa-
tion into clinical routine17,29–31. In order to create a realistic clinical scenario, we were using only pretransplant 
available variables in our analysis. Nevertheless, our data indirectly confirmed the specific significance of MVI in 
this setting, as tumor recurrence rate was significantly higher in the Milan Out/UTS In patients compared to the 
Milan In subset when MVI was not considered (Table 5).
In fact, vascular tumor invasion is one of the most important prognostic features in LT for HCC19,20. While 
macrovascular infiltration may be appropriately detected by modern radiographic imaging and generally excludes 
patients from LT, MVI may reliably be confirmed only post-LT33,34. Pretransplant tumor biopsy is inappropriate 
due to high risk of sample errors caused by intratumoral heterogeneity21. Apart from that, there is a theoretical 
risk of tumor cell seeding that might affect posttransplant prognosis35.
Since tumor load correlates with risk of MVI and poor grading36,37, clinical surrogate markers of tumor 
aggressiveness are essential for safely expanding macromorphometric selection limits. In the past, response to 
Figure 5. In the UTS In subset, RFS rates at 3- and 5-years post-LT were significantly higher in PET-negative 
patients (94.9%; 94.9%) as compared to patients with 18F-FDG-avid tumors (48.3%; 48.3%; log rank < 0.001).
Variable p value HR (95%CI) p value
Male gender 0.768
Age recipients’ > 60 y 0.739
Viral disease (n) 0.354
Child B/C 0.036
(Lab.)MELD > 20 0.010
AFP prior to LT > 400 ng/ml 0.028
No TACE pre-LT 0.326
Multiple HCC nodules* 0.768
Maximum HCC nodule size > 5 cm* 0,686
Maximum total tumor 
diameter > 10 cm* 0.253
Number HCC nodules > 3* 0.768
PET+ status 0.001 19.25 (2.961–125.161) 0.007
Table 4. Prognostic variables for HCC recurrence in UTS Out patients (n = 31). *According to pretransplant 
radiographic staging. AFP – alpha-fetoprotein. CI – confidence interval. HCC – hepatocellular carcinoma. LT 
– liver transplantation. MELD – model for end-stage liver disease. PET – positron emission tomography. TACE 
– transarterial chemoembolization. UTS – Up-to-seven criteria.
www.nature.com/scientificreports/
8SCIenTIfIC REPORTS | 7: 14176  | DOI:10.1038/s41598-017-14430-9
TACE38, AFP-level39, C-reactive protein40, PIVKA II41, yglutamyltransferase42 and 18F-FDG PET22,24 were applied 
for biological tumor evaluation. Among them, increased 18F-FDG uptake on PET was shown to be highly associ-
ated with unfavorable histopathology and risk of tumor recurrence43–45.
18F-FDG PET is a well-established non-invasive tool for metabolic imaging of different malignancies46. Like 
glucose, 18F-FDG is uploaded by the tumor cells via several overexpressed glucose transporters. Well differen-
tiated HCC nodules exhibit an enzyme activity that is not different to that of normal liver tissue, resulting in a 
similar FDG uptake pattern. On contrary, poorly differentiated HCCs are characterized by enhanced FDG uptake 
pattern as compared to the surrounding healthy liver regions. In contrast to several other cancers, 18F-FDG-PET 
is therefore not appropriate for detection of HCC, but rather for evaluation of metabolic tumor viability47.
In fact, the application of 18F-FDG PET was recently demonstrated to select suitable liver transplant patients 
with HCC beyond MC and UCSF criteria48–51. Although MVI plays an essential role for the prognostic reliability 
of the UTS criteria17,29–31, the are no comparable investigations in this context.
Our study impressively confirmed that enhanced 18F-FDG uptake on pretransplant PET is a valuable indicator 
of biological tumor aggressiveness and poor outcome (Table 6). Positive PET-status was even identified as most 
powerful independent clinical predictor of HCC recurrence in our series (Table 2). Apart from that, we were able 
to demonstrate that combining the clinical UTS criteria with FDG-PET leads to an extremely low tumor relapse 
Figure 6. In the UTS Out subset, 3- and 5-year RFS rates were 93.8% and 87.1% in PET-negative, but only 
35.7% and 19% in PET-positive patients, respectively (log rank < 0.001).
Figure 7. There was no significant difference in RFS between UTS In patients and PET-negative UTS Out 
patients (log rank = 0.534), whereas it was significantly worse in PET-positive beyond UTS patients (log 
rank < 0.001).
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risk (Fig. 5). Only 3 of 59 non- 18F-FDG-avid (5.1%), but 13 of 26 PET-positive (50%) patients meeting the UTS 
criteria developed tumor recurrence (p < 0.001).
However, by strictly adhering to this selection concept, more than 30% of our UTS In patients would have 
been excluded from LT, with almost half of them still being tumor-free alive after 5 years (Fig. 5). The number of 
liver transplants had thereby been reduced from originally 66 meeting standard criteria (Milan In) to 59 fulfilling 
the novel hybrid criteria set (UTS In + PET-negative). Rather, our data pointed out that the MC are excellent for 
selecting suitable liver transplant patients (Figs 1 and 2), whereas further biological tumor evaluation is necessary 
beyond the Milan boundaries (Table 5).
As shown in Fig. 8, 18F-FDG PET identifies those Milan Out/UTS In tumors that have an aggressive biolog-
ical potential. Probably due to the small sample size (n = 19), the survival difference between PET-positive and 
PET-negative patients was just not significant (Fig. 8). However, non-18F-FDG-avid Milan Out/UTS In patients 
were able to achieve a 5-year RFS rate of 80%, which was comparable to Milan In patients (86.2%, Fig. 9). This 
needs to be validated in a larger study cohort.
Noteworthy, we did not find significant outcome differences between Milan Out/UTS In and beyond UTS 
patients, although tumor load was significantly higher in the UTS Out cohort. One explanation might be that 
Milan In 
n = 66
Milan Out/UTS 
In n = 19
UTS Out 
n = 31
p value Milan In vs. 
Milan Out/UTS In
p value Milan 
In vs. UTS Out
p value Milan Out/
UTS In vs. UTS Out
Median AFP prior to LT in ng/ml (range) 45 (1.5–13300) 100 (2.7–5580)
150 
(3.2–46930) 0.602 0.144 0.491
TACE pre-LT 42 (63.6%) 12 (63.2%) 22 (71%) 0.970 0.612 0.566
Multiple HCC nodules* 21 (31.8%) 14 (73.7%) 23 (74.2%) 0.001 <0.001 0.968
Median max. HCC nodule size in cm (range)* 3 (1–5) 4.5 (2–6) 6 (3–20) <0.001 <0.001 0.005
Median total tumor diameter in cm (range)* 4 (1–9) 8 (5.6–14) 10. (5.8–20) <0.001 <0.001 0.004
Median number HCC nodules (range)* 1 (1–3) 2 (1–5) 3 (1–8) <0.001 <0.001 0.322
PET+ status 17 (25.8%) 9 (47.4%) 15 (48.4%) 0.072 0.027 0.944
Microvascular invasion 18 (27.3%) 8 (42.1%) 17 (54.8%) 0.216 0.008 0.382
Poor tumor differentiation 9 (13.6%) 5 (26.3%) 7 (22.6%) 0.189 0.268 0.764
HCC recurrence 9 (13.6%) 7 (36.8%) 13 (41.9%) 0.023 0.002 0.721
Overall survival rate 0.001 0.004 0.488
 3 year 89.4% 73.7% 74.2%
 5 year 81.7% 62.2% 63.2%
Recurrence-free survival rate 0.017 0.002 0.837
 3 year 86.2% 63.2% 66.7%
 5 year 86.2% 63.2% 55.1%
Table 5. Clinicopathologic differences between Milan In patients (n = 66), Milan Out/UTS In patients (n = 19) 
and UTS Out patients (n = 31). *According to pretransplant radiographic staging. AFP – alpha-fetoprotein. 
HCC – hepatocellular carcinoma. LT – liver transplantation. PET – positron emission tomography. TACE – 
transarterial chemoembolization. UTS – Up-to-seven criteria.
Figure 8. In the Milan Out/UTS In subset, 5-year RFS rates were 80% in PET-positive and 44.4% in PET-
negative patients (log rank = 0.078), respectively.
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both subgroups did not differ regarding aggressive histopathologic variables (Table 5). According to this finding, 
the prognostic significance of tumor load may reach a plateau beyond the UTS limit. In fact, none of macro-
morphometric features but only positive PET-status was identified as an independent clinical promoter of HCC 
relapse in beyond UTS patients (Table 4).
Furthermore, outcome was not significantly different between patients meeting the UTS criteria and 
PET-negative patients exceeding them (Fig. 7). This interesting result indicates that biological tumor activity is 
the major prognostic determinant in advanced HCC stages. D’Amico et al. recently identified poor grading and 
MVI as the only independent predictors of tumor relapse in a series of 124 liver recipients with HCC beyond the 
UTS criteria, which supports this assumption on a histopathologic basis31. If being confirmed in large prospective 
trials, our data support the implementation of a purely tumor-biology based selection approach, as was already 
favored by others52.
There are several limitations of our study. First, it was a retrospective investigation with all the possible disad-
vantages of this study design. Second, the number of HCC patients beyond MC but still meeting the UTS criteria 
was rather low. Another critical point is that we have stratified our data according to semiquantitative and not 
quantitative PET results, which did not allow for further risk stratification in the 18F-FDG-avid subset. In contrast, 
Figure 9. Recurrence-free survival was not significantly different between Milan In patients and those with 
PET-negative Milan Out/UTS In tumors (log rank = 0.639).
PET–(n = 75) PET +  (n = 41) p value
Median AFP prior to LT in ng/ml (range) 50 (3.2–5580) 146 (1.5–46930) 0.077
Multiple HCC nodules* 34 (45.3%) 24 (58.5%) 0.174
Median max. HCC nodule size in cm (range)* 3 (1–10) 4.6 (1.4–20) 0.005
Median total tumor diameter in cm (range)* 5 (1–16) 8 (1–20) 0.005
Median number HCC nodules (range)* 1 (1–8) 2 (1–6) 0.097
Microvascular invasion <0.001
 no 66 (88%) 7 (17.1%)
 yes 9 (12%) 34 (82.9%)
Tumor differentiation 0.001
 well/moderate 68 (90.7%) 27 (65.9%)
 poor 7 (9.3%) 14 (34.1%)
 HCC recurrence 5 (6.7%) 24 (58.5%) <0.001
Overall survival rate <0.001
 3 year 97.3% 63.4%
 5 year 88.7% 46.3%
Recurrence-free survival rate <0.001
 3 year 94.6% 43.8%
 5 year 93.3% 38.1%
Table 6. Correlation of FDG-PET with tumor-specific features and outcome. *According to pretransplant 
radiographic staging. AFP – alpha-fetoprotein. HCC – hepatocellular carcinoma. LT – liver transplantation. 
PET – positron emission tomography.
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our study was powered by a large PET data collection and a well-documented long-term follow-up. Apart from 
that, only preoperatively available tumor characteristics were used for risk analysis.
In conclusion, our study demonstrated that expansion to the clinical UTS criteria carries a considerable risk of 
selecting tumors with aggressive potential. The implementation of 18F-FDG PET improves the prognostic power 
of the UTS criteria, since it identifies patients with beneficial tumor biology. Expansion to the UTS criteria may, 
thereby, be safely realized.
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